CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice

Endocrinology

Volumn 152, Issue 10, 2011, Pages 3661-3667

  Lockie, Sarah Haas ^a,c   Czyzyk, Traci A ^b   Chaudhary, Nilika ^a   Perez Tilve, Diego ^a   Woods, Stephen C ^a   Oldfield, Brian J ^c   Statnick, Michael A ^b   Tschöp, Matthias H ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE; NORBINALTORPHIMINE; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIORAL SCIENCE; BODY WEIGHT; CONTROLLED STUDY; EXPERIMENTAL TEST; FOOD INTAKE; MALE; MOOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AFFECT; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; EATING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 80053159809     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1220     Document Type: Article

References (50)

1. Cooke D, Bloom S 2006 The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 5:919-931 (Pubitemid 44660605)
2. O'Brien PE, McPhail T, Chaston TB, Dixon JB 2006 Systematic review of medium-term weight loss after bariatric operations. Obes Surg 16:1032-1040 (Pubitemid 44221269)
3. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC, Lefur G 1995 Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947
4. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, DeLepeleire I, Cilissen C, Cote J, Rosko K, Gendrano III IN, Nguyen AM, Gumbiner B, Rothenberg P, De Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, et al. 2008 The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78
5. Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, Tschöp MH 2009 The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 60:93-98
6. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M 2009 Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Rev [Erratum (2009)10:586] 10:564-575
7. Yeomans MR, Gray RW 1997 Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect. Physiol Behav 62:15-21 (Pubitemid 27303759)
8. De Zwaan M, Mitchell JE 1992 Opiate antagonists and eating behavior in humans - a review. J Clin Pharmacol 32:1060-1072 (Pubitemid 23033657)
9. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D 1987 High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22:35-42 (Pubitemid 17229950)
10. Atkinson RL 1982 Naloxone decreases food-intake in obese humans. J Clin Endocrinol Metab 55:196-198 (Pubitemid 13250350)
11. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA 2009 Rational design of a combination medication for the treatment of obesity. Obesity 17:30-39 (Pubitemid 50324544)
12. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon Jr WA 2007 Anxiolytic-Like effects of κ-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323:838-845 (Pubitemid 350146065)
13. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens Jr WC, Jones RM, Portoghese PS, Carlezon Jr WA 2003 Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323-330 (Pubitemid 36373867)
14. Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, Schwarzer C 2009 Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34:775-785
15. Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W 2005 Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 48:1097-1104 (Pubitemid 40725982)
16. Cichewicz DL, Welch SP, Smith FL 2005 Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal Δ(9)- tetrahydrocannabinol. Eur J Pharmacol 525:74-82 (Pubitemid 41689024)
17. Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, Welch SP 2006 Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by Δ(9)-tetrahydrocannabinol. Eur J Pharmacol 539:57-63 (Pubitemid 44208807)
18. Cota D, Tschöp MH, Horvath TL, Levine AS 2006 Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107 (Pubitemid 43782532)
19. Ansonoff MA, Zhang J, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, Roth BL, Pintar JE 2006 Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of κ-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641-648 (Pubitemid 44061239)
20. Schuller AGP, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, Pasternak GW, Pintar JE 1999 Retention of heroin and morphine-6 β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151-156 (Pubitemid 30491315)
21. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE 1999 Retention of supraspinal δ-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 24:243-252 (Pubitemid 29466162)
22. Endoh T, Matsuura H, Tanaka C, Nagase H 1992 Nor-binaltorphimine - a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42
23. Tepperman FS, Hirst M, Smith P 1983 Brain and serum levels of naloxone following peripheral administration. Life Sci 33:1091-1096 (Pubitemid 13000910)
24. Porsolt RD, Bertin A, Jalfre M 1977 Behavioral despair in mice - primary screening-test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336 (Pubitemid 8225714)
25. Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, McKinzie DL, Nomikos GG, Gehlert DR 2006 Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology 31:1135-1145 (Pubitemid 43971831)
26. Thompson VB, Heiman J, Chambers JB, Benoit SC, Buesing WR, Norman MK, Norman AB, Lipton JW 2009 Long-term behavioral consequences of prenatal MDMA exposure. Physiol Behav 96:593-601
27. Carlezon Jr WA, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM 2006 Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447 (Pubitemid 41832624)
28. Tallett AJ, Blundell JE, Rodgers RJ 2008 Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 187:417-427
29. Wilson AR, Maher L, Morgan MM 2008 Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 55:1219-1225
30. Viganò D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, Parolaro D 2005 Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology 182:527-536 (Pubitemid 41464634)
31. Cichewicz DL, Welch SP 2003 Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ(9)-tetrahydrocannabinol. J Pharmacol Exp Ther 305:812-817 (Pubitemid 36617955)
32. Del Arco I, Navarro M, Bilbao A, Ferrer B, Piomelli D, Rodríguez De Fonseca F 2002 Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. Eur J Pharmacol 454:103-104 (Pubitemid 35284372)
33. Bodnar RJ 2004 Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides 25:697-725 (Pubitemid 38681072)
34. Czyzyk TA, Nogueiras R, Lockwood JF, McKinzie JH, Coskun T, Pintar JE, Hammond C, Tschop MH, Statnick MA 2010 κ-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J 24:1151-1159
35. Pfeiffer A, Brantl V, Herz A, Emrich HM 1986 Psychotomimesis mediated by κ-opiate receptors. Science 233:774-776
36. Hohmann AG, Herkenham M 2000 Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37:71-80 (Pubitemid 30366503)
37. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A 1999 Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci USA 96:5786-5790 (Pubitemid 29234696)
38. Gerald TM, Ward GR, Howlett AC, Franklin SO 2006 CB, knockout mice display significant changes in striatal opioid peptide and D-4 dopamine receptor gene expression. Brain Res 1093:20-24 (Pubitemid 43946401)
39. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R 2002 Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors. J Neurosci 22:1146-1154 (Pubitemid 34141794)
40. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG 2003 The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544-553 (Pubitemid 36315302)
41. Takahashi E, Katayama M, Niimi K, Itakura C 2008 Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 589:149-156
42. Borsini F, Meli A 1988 Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160 (Pubitemid 18040687)
43. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M 2008 Involvement of κ-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry 63:286-292
44. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J 2010 Use patterns and self-reported effects of Salvia divinorum An Internet- based survey. Drug Alcohol Depend 111:250-256
45. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikawa K, Uezono Y 2008 μ-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108:308-319
46. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ 2006 Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781 (Pubitemid 44308340)
47. Parolaro D, Rubino T, Viganò D, Massi P, Guidali C, Realini N 2010 Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 11:393-405
48. Spanagel R, Herz A, Shippenberg TS 1992 Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050
49. Ford CP, Mark GP, Williams JT 2006 Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26:2788-2797 (Pubitemid 43357862)
50. Després JP, Golay A, Sjöström L, Rimonabant Obesity Lipids Study Group 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134